1. Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N.
2. Benajmim E., Levy D., Vaziri S. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;171:840-4.
3. Reiffel J., Curtis A. Antiarrhythmic Drugs. In: ACCSAP 4: Adult Clinical Cardiology Self-Assessment Program. American College of Cardiology, 2005. p.15-53.
4. ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. Circulation 2006;114:700-52.
5. Miller J., Zipes D. Management of the patient with cardiac arrhythmias. In: Heart Disease: a Textbook of Cardiovascular Medicine. Ed. by E. Braunwald, D.P. Zipes, P. Libby. Philadelphia: Saunders, 2001. p.731- 736.
6. Татарский Б.А. Бессимптомная форма фибрилляции предсердий. Сердечная недостаточность 2002;(5):217-21.
7. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121-8.
8. Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the nitial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96.
9. Сулимов В.А. Медикаментозная терапия фибрилляции предсердий: настоящее и будущее. Кардиология 1999;(7):69-75.
10. Wijffels M., Kirchhof C., Dorland R., et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954–68.
11. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415:219-26.
12. Slavik R., Tisdale J., Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-52.
13. Hohnloser S., Kuch K., Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) - a randomised trial. Lancet 2000;356:1789-94.
14. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6.
15. Wyse D., Waldo A., DiMarco J., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
16. Pelargonio G., Prystowsky E. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract Cardiovasc Med 2005;2:514-21.
17. Prystowsky E., Benson D., Fuster V., et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Sub�committee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262-77.
18. Camm J, Haffajee C., Sheldon R, et al. International Consensus Roundtable on Atrial Fibrillation. Cardiol Rev 2000;17(Suppl):1-19.
19. Capucci A., Villani G.Q., Piepoli M.F. Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. Am J Cardiol 2003;92:1345-7.
20. Lenzi T., Boriani G., Botto G., et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
21. Татарский Б.А. Стратегия «таблетка в кармане» при купировании фибрилляции предсердий. Росс кардиол журн 2005;(1):45-54.
22. Фомина И.Г., Таризманова А.И., Ветлужский А.В., и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваск тер профилакт 2005;(4):65-69.
23. Prystowsky E.N. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000;85:3-11.
24. Li H., Natale A., Tomassoni G., et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol 1999;84:1096-8.
25. Reisinger J., Gatterer E., Lang W. et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-24.
26. Khan I.A., Mehta N.J., Gowda R.M. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;89:239-48.
27. Greenbaum R.A., Campbell T.J., Channer K.S., et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (European and Australian Multicenter Evaluative Research on atrial fibrillation Dofetilide) Study. Circulation 1998;98:1633-9.
28. Singh S., Zoble R.G., Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90.
29. UK Propafenone PSVT Study Group. A randomized, placebocontrolled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-7.
30. Bianconi L., Mennuni M., Lukic V., et al. Effects of oral propafenone administration before electrical cardioversion of atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996;28:700-6.
